Prestige Consumer Healthcare Inc.
PBH
$46.75
+1.79%
Prestige Consumer Healthcare Inc. is a leading pure-play over-the-counter (OTC) healthcare company, owning a diverse portfolio of established brands in niche categories such as eye care (Clear Eyes), motion sickness (Dramamine), and feminine hygiene (Monistat, Summer's Eve). The company operates as a category leader in several stable consumer health segments, leveraging brand trust and professional recommendations to maintain its market position. The current investor narrative is dominated by its recent strategic acquisition of the Breathe Right® nasal strips brand, aimed at expanding its reach into adjacent wellness categories, which is being evaluated for its potential to drive future growth and financial accretion against a backdrop of significant recent stock price weakness.…
PBH
Prestige Consumer Healthcare Inc.
$46.75
Related headlines
Investment Opinion: Should I buy PBH Today?
Rating: Hold. The core thesis is that PBH presents a compelling value proposition based on fundamentals, but the severe negative momentum and lack of catalysts warrant caution until the price action stabilizes. The single analyst's implied target suggests 21% upside, but this is not a strong consensus.
Supporting Evidence: The stock is cheap on a forward P/E basis at 9.65x, a 36% discount to its trailing P/E of 15.09x. Profitability is strong with net margins of 17.48% and gross margins of 52.78%. The balance sheet is a key strength, with a debt-to-equity of 0.026 and a current ratio of 3.57, providing significant financial flexibility. Free cash flow generation appears healthy, as indicated by a price-to-cash-flow ratio of 10.82.
Risks & Conditions: The two biggest risks are the continuation of the severe downtrend and a failure of the Breathe Right acquisition to meet expectations. This Hold rating would upgrade to a Buy if the stock establishes a technical base above its 52-week low and shows evidence of the acquisition being accretive in upcoming financials. It would downgrade to a Sell if the stock breaks below $42.62 on high volume, signaling a breakdown of support. Relative to its own history (inferred from the massive PE compression) and given its strong financials, the stock appears undervalued, but it is fairly valued relative to the current overwhelming negative sentiment.
Sign up to view all
PBH 12-Month Price Forecast
PBH is a classic battleground between value and momentum. The fundamentals—low valuation, high profitability, and a pristine balance sheet—scream opportunity. However, the price action—a 46% annual decline and intense underperformance—screams avoidance. The outcome hinges almost entirely on the successful execution of the Breathe Right acquisition to provide the earnings catalyst needed to break the negative feedback loop. The stance is neutral with medium confidence because while the risk/reward appears favorable for patient investors, the timing of a turnaround is highly uncertain. The stance would turn bullish on confirmation of earnings acceleration and technical stabilization above $50; it would turn bearish on a breakdown below the $42.62 support level.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Prestige Consumer Healthcare Inc.'s 12-month outlook, with a consensus price target around $60.77 and implied upside of +30.0% versus the current price.
Average Target
$60.77
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$37 - $61
Analyst target range
Analyst coverage for PBH is extremely limited, with only one analyst providing estimates, indicating insufficient institutional coverage which can lead to higher volatility and less efficient price discovery typical of smaller-cap stocks. The single analyst projects an average EPS of $5.87 for the coming year, which, against the current price and forward PE of 9.65x, implies an estimated price target of approximately $56.65, representing a potential upside of about 21% from the current price of $46.75, suggesting this lone analyst holds a bullish view. The target range has a low estimate of $5.60 and a high of $6.30, a relatively tight spread of about 12%, which could indicate higher conviction in the earnings forecast despite the lack of broad coverage, though the absence of explicit price targets and a consensus recommendation limits the strength of any sentiment signal.
Bulls vs Bears: PBH Investment Factors
The investment debate for PBH centers on a clash between its fundamentally sound financial profile and its technically disastrous price action. The bull case is built on a fortress balance sheet, high profitability, and a compellingly low forward valuation that prices in significant earnings growth. The bear case is dominated by a severe, market-lagging downtrend that reflects deep pessimism and a lack of near-term catalysts. Currently, the bearish technical momentum and sentiment are the dominant forces, overwhelming the solid fundamentals. The single most important tension is whether the company's stable cash flows and the potential from the Breathe Right acquisition can soon provide a positive earnings catalyst strong enough to reverse the powerful negative momentum and validate the low valuation.
Bullish
- Extremely Strong Balance Sheet: The company has minimal financial risk with a debt-to-equity ratio of just 0.026 and a robust current ratio of 3.57. This provides ample liquidity to navigate downturns and fund strategic acquisitions like Breathe Right without over-leveraging.
- Attractive Forward Valuation: The stock trades at a forward P/E of 9.65x, which is a significant discount to its trailing P/E of 15.09x. This implies the market expects a substantial earnings increase, potentially driven by the accretive Breathe Right acquisition and cost synergies.
- High Profitability in Stable Niches: PBH maintains strong pricing power with a gross margin of 52.78% and a net margin of 17.48%. Its portfolio of leading OTC brands in defensive categories like eye care and feminine hygiene generates consistent, high-margin cash flow.
- Deeply Oversold Technical Condition: The stock is down 46.33% over the past year and trades at just 8% of its 52-week range from low to high, near its 52-week low of $42.62. This extreme pessimism, coupled with a high short ratio of 5.64, sets up a potential for a sharp relief rally on any positive catalyst.
Bearish
- Severe and Accelerating Price Downtrend: The stock has dramatically underperformed the market, with a 1-month decline of -18.79% vs. SPY's +5.6% gain, resulting in a relative strength of -24.39. This intense selling pressure indicates a fundamental lack of positive catalysts and severe negative sentiment.
- Extremely Limited Analyst Coverage: Only one analyst provides estimates for PBH, indicating a lack of institutional interest and research. This can lead to higher volatility, less efficient price discovery, and increased risk for investors due to poor information flow.
- Revenue Growth Uncertainty: While analyst revenue is estimated at $1.39B, the absence of specific quarterly growth data in the analysis makes it difficult to confirm the top-line trajectory. The company's mature, niche OTC portfolio may face challenges in generating meaningful organic growth.
- High Volatility and Downside Risk: The stock has a maximum drawdown of -48.45% and is currently trading just 9.7% above its 52-week low. This high volatility profile, combined with its small-cap status, makes it a risky holding prone to sharp declines on negative news.
PBH Technical Analysis
The stock is in a pronounced and sustained downtrend, evidenced by a 1-year price change of -46.33% and trading near the bottom of its 52-week range, with the current price of $46.75 representing only 8% of the distance from the 52-week low of $42.62 to the high of $89.37. This positioning near multi-year lows suggests the stock is deeply oversold, presenting a potential value opportunity but also reflecting severe negative sentiment and fundamental concerns. Recent momentum is decisively negative and accelerating the longer-term downtrend, with a 1-month decline of -18.79% and a 3-month drop of -30.00%, significantly underperforming the SPY's gains of 5.6% and 8.42% over the same periods, respectively. This severe underperformance, highlighted by a 1-month relative strength of -24.39, indicates intense selling pressure and a lack of positive catalysts. Key technical levels are clearly defined, with immediate support at the 52-week low of $42.62 and resistance far above near the 52-week high of $89.37; a breakdown below $42.62 would signal a continuation of the bearish trend, while any recovery would face substantial overhead supply. The stock's high short interest, with a short ratio of 5.64, combined with a maximum drawdown of -48.45%, underscores its elevated volatility and heightened risk profile for investors.
Beta
0.40
0.40x market volatility
Max Drawdown
-48.5%
Largest decline past year
52-Week Range
$43-$89
Price range past year
Annual Return
-46.3%
Cumulative gain past year
| Period | PBH Return | S&P 500 |
|---|---|---|
| 1m | -18.8% | +4.1% |
| 3m | -30.0% | +8.4% |
| 6m | -22.1% | +12.0% |
| 1y | -46.3% | +24.4% |
| ytd | -23.6% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PBH Fundamental Analysis
Revenue trajectory analysis is limited as specific quarterly revenue and growth rate data are not available in the provided dataset; however, analyst estimates project full-year revenue around $1.39 billion, suggesting the market anticipates stable, if not spectacular, top-line performance. The company is profitable, with a trailing net margin of 17.48% and a gross margin of 52.78%, indicating strong pricing power and cost management within its niche OTC categories. Profitability metrics show a return on equity (ROE) of 10.08% and return on assets (ROA) of 5.61%, which are respectable but not exceptional, pointing to adequate but not stellar capital efficiency. The balance sheet appears exceptionally strong with minimal financial risk, evidenced by a very low debt-to-equity ratio of 0.026 and a robust current ratio of 3.57, indicating ample liquidity to meet short-term obligations. Free cash flow generation appears healthy based on a price-to-cash-flow ratio of 10.82, suggesting the company generates sufficient internal cash to fund operations and potential acquisitions like Breathe Right without over-reliance on external debt.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PBH Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE stands at 15.09x, while the forward PE is notably lower at 9.65x, implying the market expects a significant earnings increase in the coming year, potentially driven by cost synergies or the accretive nature of recent acquisitions. Peer comparison is challenging as industry average multiples are not provided in the data; however, a trailing PE of 15.09x for a stable, profitable OTC healthcare company with a strong balance sheet does not appear egregiously expensive on an absolute basis. Historical context for the stock's own valuation range is unavailable due to missing historical ratios data, preventing an assessment of whether the current multiple is at a historical premium or discount, which limits the ability to gauge if current pessimism is fully priced in.
PE
15.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: PBH's primary financial risk is not leverage but growth stagnation. With a forward P/E of 9.65x implying high earnings growth expectations, the risk is that revenue, estimated at $1.39B, fails to accelerate. The company's respectable but not stellar ROE of 10.08% and ROA of 5.61% suggest capital efficiency has room for improvement. Execution risk on the Breathe Right acquisition is paramount; failure to achieve projected synergies would directly undermine the earnings growth priced into the forward multiple, potentially triggering further multiple compression.
Market & Competitive Risks: The stock faces extreme valuation compression risk, having fallen 46% in a year while the broader market rose 25%. Trading near multi-year lows, it risks being perceived as a value trap. As a small-cap stock in the competitive OTC healthcare space, it is vulnerable to larger competitors with greater marketing budgets. Its high short interest ratio of 5.64 indicates a crowded bearish bet, which can lead to violent short-covering rallies but also reflects a pervasive lack of confidence from sophisticated investors.
Worst-Case Scenario: The worst-case scenario involves the Breathe Right acquisition failing to drive expected growth, combined with market share erosion in core brands like Monistat or Clear Eyes. This would lead to an earnings miss, causing the lone analyst to downgrade estimates. With no dividend yield (0%) to provide a floor, sentiment could drive the stock to test and break its 52-week low of $42.62. A realistic downside from the current price of $46.75 would be a re-test of that low, representing a potential loss of approximately -9%. In a broader market sell-off, the stock could fall further, revisiting levels implied by its maximum drawdown of -48.45%.
FAQ
The key risks are: 1) Momentum & Sentiment Risk: The stock is in a severe downtrend (-46% YoY) with high short interest, indicating pervasive negative sentiment that can persist. 2) Execution Risk: The recently acquired Breathe Right brand must be successfully integrated and meet growth expectations to justify the forward earnings multiple. 3) Liquidity & Coverage Risk: With only one analyst covering the stock, information is scarce, which can lead to higher volatility and inefficient pricing. 4) Competitive Risk: As a smaller player in the OTC healthcare space, it faces constant competition from larger rivals with greater resources.
The 12-month forecast is bifurcated, with a 60% probability base case target range of $52-$60, centered around the single analyst's implied target of ~$56.65. The bull case (25% probability) sees a successful acquisition driving the stock to $65-$75, while the bear case (15% probability) envisions further disappointment pushing the stock to retest its 52-week low between $42 and $48. The most likely scenario is the base case, which assumes the company meets its earnings estimate of $5.87 and the stock's valuation stabilizes as the negative momentum subsides.
Based on fundamentals, PBH appears significantly undervalued. It trades at a forward P/E of 9.65x, which is a deep discount to its own trailing P/E of 15.09x and suggests the market expects strong earnings growth. Its price-to-cash-flow of 10.82 and EV/EBITDA of 8.38 also suggest a reasonable valuation for a stable cash-generating business. However, valuation is relative to sentiment, and the market is currently assigning a large discount due to poor price momentum and growth concerns. The valuation implies the market expects the company to execute perfectly on its growth plans; any stumble would justify the current low multiple.
PBH is a high-risk, high-potential-reward stock that may be a good buy for a specific type of investor. For a contrarian value investor with a long time horizon and the stomach for volatility, the current price offers an attractive entry point into a company with a strong balance sheet (D/E 0.026) and high profitability (17.5% net margin). The implied 21% upside to the analyst's target is compelling. However, it is not a good buy for risk-averse or short-term investors, given its 46% annual decline, high short interest (5.64), and lack of near-term positive catalysts. A good buy is conditional on believing the Breathe Right acquisition will succeed and that the technical downtrend is exhausted.
PBH is strictly suitable for long-term investment, with a suggested minimum holding period of 2-3 years. The stock's high volatility (max drawdown -48.45%), lack of dividend, and current distressed technical condition make it a poor candidate for short-term trading. A long-term horizon allows time for the Breathe Right acquisition to be integrated and contribute to earnings, for sentiment to potentially improve, and for the deep value represented by the low forward P/E of 9.65x to be realized. Short-term traders would be exposed to whipsaw action driven by sentiment shifts around sparse news flow.